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Open access under the EMammalian target of rapamycin (mTOR), a central regulator of protein synthesis in neurons, has been
implicated in synaptic plasticity and memory. Here we show that mTOR inhibition by rapamycin in
the basolateral amygdala (BLA) or dorsal hippocampus (DH) impairs both formation and reconsolidation
of memory for inhibitory avoidance (IA) in rats. Male Wistar rats received bilateral infusions of vehicle or
rapamycin into the BLA or DH before or after IA training or retrieval. Memory retention was tested at dif-
ferent time points after drug infusion. Rapamycin impaired long-term IA retention when given before or
immediately after training or retrieval into the BLA. When infused into the DH, rapamycin produced
memory impairment when given before training or immediately after retrieval. The impairing effects
of post-retrieval rapamycin required memory retrieval and were not reversed by a reminder shock.
The results provide the ﬁrst evidence that mTOR in the BLA and DH might play a role in IA memory
reconsolidation.
 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Gene expression and protein synthesis are required for long-
term memory formation. The protein synthesis-dependent phase
whereby newly learned, initially labile, memory traces become sta-
bilized is known as consolidation (McGaugh, 2000). Consolidation
of memory for inhibitory avoidance (IA), a fear conditioning para-
digm in which rats or mice learn to avoid a context previously
associated with a footshock, is blocked by protein synthesis inhib-
itors given systemically or infused directly into the dorsal hippo-
campus (DH) or the basolateral amygdala (BLA) (Flood, Bennett,
Orme, & Rosenzweig, 1975; Milekic, Pollonini, & Alberini, 2007;
Quevedo et al., 1999; Stäubli, Faraday, & Lynch, 1985).
The traditional consolidation theory has been challenged by a
wave of studies showing that reactivation of a previously consoli-
dated fear-motivated memory during retrieval might render this
memory again susceptible to disruption by protein synthesis inhib-
itors. Thus, a reactivated labile memory would need to undergo aacology, Institute for Basic
Sul, Rua Sarmento Leite, 500
gre, RS, Brazil. Fax: +55 51
ler).
lsevier OA license.protein synthesis-dependent phase of re-stabilization, a process
generally referred to as reconsolidation (Alberini, 2011; Debiec, Le-
Doux, & Nader, 2002; Nader, Schafe, & Le Doux, 2000; Sara, 2000),
although the exact nature of this phenomenon remains a matter of
debate (Alberini, 2005, 2011; Amaral, Osan, Roesler, & Tort, 2008;
Miller & Sweatt, 2006; Nader & Hardt, 2009). In IA studies, evi-
dence from experiments using systemic or intra-BLA injections of
protein synthesis inhibitors have suggested that memory for IA
undergoes reconsolidation (Milekic & Alberini, 2002; Milekic
et al., 2007), whereas other studies have found that impairments
in IA memory produced by administration of drugs around the
time of retrieval are transient and may not be attributed to a deﬁcit
of memory storage (Amaral, Luft, Cammarota, Izquierdo, & Roesler,
2007; Power, Berlau, McGaugh, & Steward, 2006). From a transla-
tional point of view, understanding the molecular mechanisms
underlying the reconsolidation of fear memories and the effects
of pharmacological treatments on reconsolidation has clinical
implications for the identiﬁcation of novel treatment opportunities
for fear-related neuropsychiatric disorders including post-trau-
matic stress disorder (PTSD) (Debiec & LeDoux, 2006; Tronel &
Alberini, 2007).
Mammalian target of rapamycin (mTOR) is a central regulator
of protein synthesis in neurons. mTOR is a protein kinase that acts
as central component of two multi-protein signaling complexes,
mTORC1 and mTORC2. The mTORC1 pathway integrates signaling
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the activity of downstream protein kinase pathways, including
phosphoinositide 3-kinase (PI3K). mTOR regulates mRNA transla-
tion by controlling the phosphorylation state of the eukaryotic ini-
tiation factor 4E binding protein (4E-BP1) and p70s6 kinase
(p70s6K) (for a review, see Hoeffer & Klann, 2010). Rapamycin
(sirolimus), a naturally occurring macrolide derived from the soil
bacterium Streptomyces hygroscopius, potently inhibits mTORC1
activity by associating with the intracellular protein FKBP12, and
together they bind the FKBP12-rapamycin-binding (FRB) domain
of mTOR, thus preventing mTOR-protein complex formation (for
reviews, see Guertin & Sabatini, 2009; Hoeffer & Klann, 2010).
Recent studies have used rapamycin as a tool to investigate the
role of mTOR in memory formation and reconsolidation. Systemic
administration of rapamycin impaired the consolidation of mem-
ory for contextual fear conditioning (CFC) and reduced subsequent
memory retention when given after reactivation (Blundell, Kouser,
& Powell, 2008). Rapamycin given systemically also impaired fear-
potentiated startle to a shock-paired context, but did not disrupt
startle increases when an odor cue was used (Glover, Ressler, & Da-
vis, 2010). Consolidation and reconsolidation of CFC were impaired
by rapamycin infused directly into the DH (Gafford, Parsons, &
Helmstetter, 2011), and long-term retention of trace fear memory
was impaired by rapamycin infused into the medial prefrontal cor-
tex in rats (Sui, Wang, & Li, 2008). The role of mTOR in memory for-
mation and reconsolidation in the BLA is less understood. One
study has indicated that rapamycin given into the amygdala either
after training or retrieval reduced memory for cued fear condition-
ing, however that study did not verify whether memory reactiva-
tion was required for the effect of post-retrieval rapamycin and
whether the effect was long-lasting or could recover with time
(Parsons, Gafford, & Helmstetter, 2006).
Only two previous studies examined the role of mTOR in mem-
ory for IA, and their ﬁndings indicate that IA memory consolidation
is dependent on mTOR and sensitive to rapamycin in the DH
around the time of training and 3 h after training (Bekinschtein
et al., 2007; Slipczuk et al., 2009). Previous studies have not exam-
ined whether mTOR is involved in IA reconsolidation, or the role of
mTOR in the amygdala in memory for IA. Here we used rapamycin
infusions to investigate the effects of mTOR inhibition in the BLA or
DH, around the time of acquisition or retrieval, on IA memory.2. Methods
2.1. Animals
Adult male Wistar rats (340–440 g at time of surgery) were
obtained from the institutional breeding facility (CREAL, ICBS,
UFRGS). Animals were housed ﬁve per cage in plastic cages with
sawdust bedding, and maintained on a 12 h light/dark cycle at a
room temperature of 22 ± 1 C. The rats were allowed ad libitum
access to standardized pellet food and water. All experiments took
place between 9 AM and 6 PM. All experimental procedures were
performed in accordance with the National Institutes of Health
(NIH) Guide for the Care and Use of Laboratory Animals and were
approved by the institutional animal care committee under
protocol number 09-641.2.2. Surgery
Animals were implanted under anesthesia with ketamine
(75 mg/kg) and xylasine (25 mg/kg) with bilateral 14-mm or
9.0-mm, 23-gauge guide cannulae aimed 1.0 mm above the BLA
or CA1 area of the DH respectively, as described in previous studies
(Quevedo et al., 1999; Roesler et al., 2003). Coordinates (BLA,anteroposterior, 2.8 mm from bregma, mediolateral, ±4.8 mm
from bregma, ventral, 7.5 mm from skull surface; DH anteropos-
terior, 4.3 mm from bregma; mediolateral, ±3.0 mm from breg-
ma; ventral, 2.0 mm from skull surface) were obtained from the
atlas of Paxinos and Watson (2007). Animals were allowed to
recover at least 7 days after surgery.
2.3. Drugs and infusion procedures
The general procedures for intra-BLA and intra-DH infusions
were as described in previous reports (Amaral et al., 2007; Queve-
do et al., 1999; Roesler et al., 2003, 2006). At the time of infusion, a
30-gauge infusion needle was ﬁtted into the guide cannula. The tip
of the infusion needle protruded 1.0 mm beyond the guide cannula
and was aimed at either the BLA or the CA1 area of the DH. Drug or
vehicle (1% dimethylsulfoxide, DMSO, in saline) were infused
during a 30-s period. The infusion needle was left in place for an
additional minute to allow diffusion of the drug away from the
needle tip.
Either 15 min before or immediately after training or the 24-h
retention test trial, rats received a bilateral 0.5-ll (BLA) or 1.0-ll
(DH) infusion of vehicle or rapamycin (600 nM dissolved in
vehicle; Sigma–Aldrich, St. Louis, USA) into either the BLA or DH.
The dose of rapamycin was chosen on the basis of previous studies
(Bekinschtein et al., 2007; Parsons et al., 2006) and pilot
experiments. Drug solutions were freshly prepared before each
experiment.
2.4. Inhibitory avoidance (IA)
We used the single-trial step-down IA conditioning as an estab-
lished model of fear-motivated memory. In step-down IA training,
animals learn to associate a location in the training apparatus (a
grid ﬂoor) with an aversive stimulus (footshock). The general pro-
cedures for IA behavioral training and retention test were de-
scribed in previous reports (Amaral et al., 2007; Quevedo et al.,
1999). The IA apparatus was a 50  25  25-cm acrylic box (Alba-
rsch, Porto Alegre, Brazil) whose ﬂoor consisted of parallel caliber
stainless steel bars (1 mm diameter) spaced 1 cm apart. A 7-cm
wide, 2.5-cm high platform was placed on the ﬂoor of the box
against the left wall.
On training trials, rats were placed on the platform and their la-
tency to step down on the grid with all four paws was measured
with a digital chronometer connected to the box control unit.
Immediately after stepping down on the grid, rats received a 0.7-
mA, 2.0-s footshock and were removed from the apparatus imme-
diately after the footshock. Retention test trials took place at differ-
ent time points after training by placing the rats on the platform
and recording their latencies to step down. No footshock was pre-
sented during retention test trials. In experiments examining pos-
sible drug effects on reconsolidation, rats that did not step down to
the grid ﬂoor within 180 s during the 24-h test trial (‘‘reactivation
session’’) were gently put on the grid ﬂoor for 3 s. Step-down laten-
cies on the retention test trial (maximum 180 s) were used as a
measure of IA memory retention. In some of the experiments,
the rats were given a retraining trial 2 weeks after the original
training, or a 0.3-mA 2.0-s reminder footshock 1 week after the ori-
ginal training (Tronel & Alberini, 2007), followed by a retention test
24 h later. Fig. 1 shows a diagram of the design of the experiments
used in this study.
2.5. Histology
Twenty-four to 72 h after behavioral testing, a 0.5-ll (BLA) or
1.0-ll (DH) infusion of a 4% methylene blue solution was given into
the BLA or DH. Rats were killed by decapitation 15 min later, and
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Fig. 1. Schematic diagram showing the design of the experiments used in the
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Fig. 2. Inhibition of mTOR by rapamycin in the BLA impairs formation of long-term
IA memory. Rats were trained in IA and tested for retention 3 and 24 h later. Vehicle
or rapamycin was infused into the BLA either before or after training. (A) Rats were
infused with vehicle (N = 9) or rapamycin (N = 9) 15 min before training. When
tested for retention 3 h after training both groups had similar latencies. In a second
retention test 24 h after training, rats given rapamycin had signiﬁcantly lower
latencies compared to controls (⁄p < 0.05). (B) Rats were infused with vehicle
(N = 11) or rapamycin (N = 11) immediately after training. When tested for
retention 24 h after training, rats given rapamycin had signiﬁcantly lower latencies
compared to controls (⁄⁄p < 0.01). (C) Rats given post-training rapamycin showed
normal IA retention after being giving a retraining drug-free 2 weeks after the
original training. There was no signiﬁcant difference between vehicle and rapamy-
cin-treated rats.
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72 h. The brains were sectioned and examined for cannulae place-
ment in the hippocampus and BLA. The extension of the methylene
blue dye was taken as indicative of diffusion of the drugs previ-
ously given to each rat, as previously described (Amaral et al.,
2007; Quevedo et al., 1999; Roesler et al., 2003, 2006). Rats with
incorrect cannula placements were excluded from the analysis.
2.6. Statistics
Data are mean + SEM retention test latencies to step-down (s).
Comparisons of training and retention test step-down latencies
between groups were performed using Mann–Whitney U tests,
two-tailed (Amaral et al., 2007; Quevedo et al., 1999; Roesler
et al., 2003, 2006). In all comparisons, p < 0.05 was considered to
indicate statistical signiﬁcance.
3. Results
3.1. Rapamycin infused into the BLA impairs consolidation of long-
term IA memory
We ﬁrst examined the effects of intra-BLA infusions of rapamy-
cin on memory for IA. Rats were given IA training and tested for
retention 3 and 24 h later. Either 15 min before (pretraining infu-
sions) or immediately after (post-training infusions) training, vehi-
cle or rapamycin was infused into the BLA. Rapamycin given
15 min before training signiﬁcantly decreased IA retention tested
at 24 h (p < 0.05), but not at 3 h after training, compared to vehi-
cle-injected controls (Fig. 2A). Rapamycin also impaired 24-hretention when infused immediately after training (p < 0.01)
(Fig. 2B). The effects of rapamycin could not be attributed to per-
manent impairment or neuronal damage, since rats given rapamy-
cin post-training showed normal retention when given a second
training drug-free 2 weeks after the original training (Fig. 2C).
Thus, rapamycin infusion in the BLA around the time of acquisition
impairs long-, but not short-term memory for IA, indicating that
mTOR in the BLA is required for IA memory consolidation.3.2. Rapamycin infused into the BLA before or after retrieval impairs
reconsolidation of IA memory
We next examined whether mTOR inhibition in the BLA would
affect reconsolidation-like processes by giving rats intra-BLA
rapamycin around the time of retrieval. BLA-implanted rats
underwent IA training followed by a retention test trial 24 h later.
Fifteen minutes before (pre-retrieval infusions), immediately after
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retention test, vehicle or rapamycin was infused into the BLA. An
additional retention test trial was carried out 48 h after training.
There were no signiﬁcant differences between groups treated with
vehicle and rapamycin in training or 24-h test latencies. Intra-BLA
rapamycin produced a decrease in IA latency in the 48-h test com-
pared to controls, when given either before (p < 0.01; Fig. 3A) or
immediately after (p < 0.05; Fig. 3B) training.
We also veriﬁed whether the impairing effect of intra-BLA rap-
amycin given after retrieval would undergo spontaneous recovery
or be ameliorated by a reminder (Fig. 3C). Rats that received intra-
BLA infusions after retrieval were again placed on the platform
1 week after the original training and their time to step down
was recorded. There was no signiﬁcant increase in the step down
latencies of rapamycin-treated rats in this trial compared to the
48-h test trial. Upon stepping down, rats were given a mild remin-
der footshock and tested again for retention 24 h later. Latencies in
the rapamycin-treated group remained signiﬁcantly reduced0
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Fig. 3. Inhibition of mTOR by rapamycin in the BLA impairs IA memory reconsolidation. (
the 24-h test, vehicle (N = 11) or rapamycin (N = 12) was infused into the BLA. When
signiﬁcantly lower latencies compared to vehicle-treated controls (⁄⁄p < 0.01). (B) Rats w
(N = 10) was infused into the BLA immediately after the 24-h test. When re-tested for r
lower latencies compared to controls (⁄p < 0.05). (C) The impairing effect of post-retrieva
shown in the previous panel were given a 0.3-mA footshock 1 week after training a
signiﬁcantly reduced compared to vehicle-treated controls (⁄⁄p < 0.01). (D) Delayed injec
hours after the 24-h test, vehicle (N = 7) or rapamycin (N = 9) was infused into the BLA. T
were trained in IA and tested for retention 48 h later. Twenty-four hours after training,
retention test. There was no signiﬁcant difference between groups.compared to controls (p < 0.05). A separate experiment using a dif-
ferent group of untrained rats conﬁrmed that the reminder shock
used (0.3 mA) was sub-threshold, i.e., it did not induce signiﬁcant
24-h retention by itself (data not shown).
Additional control experiments were performed to conﬁrm the
speciﬁcity of the effects induced by rapamycin. A ‘‘delayed infu-
sion’’ control experiment showed that intra-BLA rapamycin did
not affect IA retention when infused 6 h after the 24-h test
(Fig. 3D). Moreover, the impairing effect of rapamycin was depen-
dent on memory retrieval; a ‘‘no reactivation’’ control experiment
showed that intra-BLA rapamycin given 24 h after training failed to
affect 48-h retention in the absence of a retention test trial
(Fig. 3E).
Together, these results suggest that rapamycin infused into the
BLA either before or after retrieval impairs IA memory tested in a
subsequent retention trial compared to controls. This impairing
effect requires memory retrieval associated with the drug infusion,
does not recover spontaneously, and is not ameliorated by a0
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duce deﬁcits in IA memory reconsolidation.
3.3. Rapamycin infused into the DH before but not after training
impairs long-term IA memory
We then aimed to compare the ﬁndings from experiments using
intra-BLA infusions of rapamycin with the effects of infusions given
into the DH. Rats were trained in IA and tested for retention 3 and
24 h later. Either 15 min before or immediately after training, vehi-
cle or rapamycin was infused into the DH. There was no signiﬁcant
difference between groups in training trial latencies. Rapamycin
given 15 min before training signiﬁcantly decreased IA retention
tested at 24 h (p < 0.01), but not at 3 h after training, compared
to vehicle-injected controls (Fig. 4A). However, rapamycin did
not affect 24-h retention when infused into the DH immediately
after training (Fig. 4B). Rats given pretraining rapamycin were
capable of learning normally when given a second training trial
drug-free 2 weeks after the original training (Fig. 4C). TheseA Pretraining infusions180
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Fig. 4. Inhibition of mTOR by rapamycin in the DH before but not after training
impairs long-term IA memory. Rats were trained in IA and tested for retention 3 and
24 h later. Vehicle or rapamycin was infused into the DH either before or after
training. (A) Rats were infused with vehicle (N = 13) or rapamycin (N = 13) 15 min
before training. Both groups showed similar latencies in a retention test carried out
3 h after training. In a second retention test 24 h given after training, rats infused
with rapamycin showed signiﬁcantly lower latencies compared to vehicle-treated
rats (⁄⁄p < 0.01). (B) Rats were infused with vehicle (N = 8) or rapamycin (N = 7)
immediately after training. When tested for retention 24 h after training, both
groups showed similar latencies. There was no signiﬁcant difference between
vehicle- and rapamycin-treated rats. (C) Rats given post-training rapamycin
showed normal IA retention after a retraining drug-free 2 weeks after the original
training. There was no signiﬁcant difference between vehicle and rapamycin-
treated rats.ﬁndings suggest that mTOR inhibition in the DH before acquisition
impairs long-, but not short-term memory for IA.
3.4. Rapamycin infused into the DH after but not before retrieval
impairs reconsolidation of IA memory
In the ﬁnal set of experiments, we investigated the possible role
of hippocampal mTOR in reconsolidation-like processes. Previous
studies have indicated that the DH is not involved in IA reconsoli-
dation (Cammarota, Bevilaqua, Medina, & Izquierdo, 2004;
Taubenfeld, Milekic, Monti, & Alberini, 2001). Rats were trained
in IA and given intra-DH infusions of vehicle or rapamycin
15 min before, immediately after, or 6 h after a 24-retention test.
An additional retention test trial was carried out 48 h after train-
ing. There were no signiﬁcant differences between groups treated
with vehicle and rapamycin in training or 24 h test latencies. In-
tra-DH rapamycin did not signiﬁcantly affect 48-h retention when
infused before the 24-h test (Fig. 5A). However, rapamycin given
after the 24-h test produced a decrease in IA latency in the subse-
quent 48-h test compared to controls (p < 0.05; Fig. 5B).
As with intra-BLA infusions, the rapamycin-induced impairment
did not recover spontaneously and was not rescued by a reminder
shock (p < 0.01; Fig. 5C). Moreover, a ‘‘delayed injection’’ control
experiment showed that intra-DH rapamycin did not affect IA
retention when infused 6 h after the 24-h test (Fig. 5D). Finally,
the impairing effect of rapamycin required memory retrieval, as
shown by a ‘‘no reactivation’’ control experiment (Fig. 5E). The
results indicate that rapamycin infused into the DH after retrieval
reduces IA retention tested in a subsequent retention trial, suggest-
ing that mTOR inhibition in the DH impairs reconsolidation.
3.5. Histology
Twenty-eight rats implanted in the BLA and 10 rats implanted
in the CA1 were excluded from the analysis due to incorrect cannu-
lae placements. Fig. 6 shows representative pictures of cannula
locations and a schematic drawing of the spread of dye within
the BLA and DH.4. Discussion
Together, our results suggest that administration of the mTOR
inhibitor rapamycin directly into the BLA or DH can impair both
formation and reconsolidation of memory for IA. Only one previous
study has examined the effects of rapamycin infused into the BLA
on fear memory reconsolidation, however that study did not
address whether the impairing effects were reversible and depen-
dent on retrieval (Parsons et al., 2006). Thus, to our knowledge
here we provide the ﬁrst evidence that intra-BLA rapamycin
produces an impairment in fear memory reconsolidation that is
not ameliorated by a reminder, and that mTOR in the BLA might
be required for IA reconsolidation. Also, our ﬁndings provide the
ﬁrst evidence that pharmacological manipulation of the hippocam-
pus after retrieval can produce a deﬁcit in IA memory that does not
recover with time or exposure to a reminder. Thus, in contrast to
previous studies (Cammarota et al., 2004; Taubenfeld et al.,
2001), the present results suggest that the hippocampus might
play a role in reconsolidation of IA memory.
It remains unclear why intra-DH rapamycin impaired formation
of IA memory when given before, but not after training, whereas, in
contrast, the effects on reconsolidation were produced by infusions
given after, but not before retrieval. However, this pattern of effect
is similar to that previously observed in experiments using intra-
DH infusions of the protein synthesis inhibitor anisomycin (Quev-
edo et al., 1999; Vianna, Szapiro, McGaugh, Medina, & Izquierdo,
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(⁄⁄p < 0.01). (D) Delayed injection control. Rats were trained in IA and tested for retention 24 and 48 h later. Six hours after the 24-h test, vehicle (N = 8) or rapamycin (N = 8)
was infused into the DH. There was no signiﬁcant difference between groups. (E) No reactivation control. Rats were trained in IA and tested for retention 48 h later. Twenty-
four hours after training, vehicle (N = 10) or rapamycin (N = 12) was infused into the DH in the absence of a retention test. There was no signiﬁcant difference between groups.
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sions of rapamycin impaired 48-h retention when given either be-
fore or after retrieval, whereas intra-DH infusions had an effect
only if given after retrieval. It is possible that this pattern of effects
is related to the differential effects of protein synthesis regulated
by mTOR on the BLA and DH in fear memory. Previous ﬁndings
have suggested that fear memory reconsolidation in the BLA re-
quires protein synthesis, but not de novo mRNA synthesis (Parsons,
Gafford, Baruch, Riedner, & Helmstetter, 2006; but see Duvarci, Na-
der, & LeDoux, 2008). Increasing evidence indicates that mTOR is a
key regulator of local protein synthesis induced by synaptic activ-
ity (Jiang & Schuman, 2002; Takei et al., 2004). This local synthesis
occurs in specialized zones at dendrites through a mechanism that
does not depend on transcription. It is possible that memory recon-
solidation in the DH is supported by both global and local protein
synthesis, whereas mainly local protein synthesis is required in the
BLA, thus resulting in a more salient requirement of mTOR in the
BLA.It is also worth pointing out that rapamycin after training or
retrieval reduced, but did not completely block, IA retention, as
evidenced by the higher latencies of rapamycin-treated rats in test
trials compared to training. However, the effect sizes of rapamycin
in our study is comparable to those found in previous studies
examining the effects of rapamycin and other protein synthesis
inhibitors on reconsolidation of fear memory (Milekic et al.,
2007; Parsons et al., 2006; Taubenfeld et al., 2001).
In previous studies from our research group, the impairing
effects of pharmacological inhibitors given after IA retrieval were
transient and recovered spontaneously with time (Amaral et al.,
2007; Luft, Amaral, Schwartsmann, & Roesler, 2008). These tran-
sient effects were consistent with those observed in many other
studies on post-retrieval treatments and fear memory (for a
review, see Amaral et al., 2008). Thus, we hypothesized that the
impairing effects of post-retrieval manipulations could represent,
among other possibilities, a ‘‘transient silencing’’ of the memory
trace undergoing consolidation, rather than a blockade of
AB
Fig. 6. Infusion placements into the BLA and DH. Representative brain sections at
2.8 (BLA) and 4.3 mm from bregma showing cannula locations aimed at the BLA
and DH, and schematic diagrams of coronal sections of the rat brain, adapted from
the atlas of Paxinos andWatson (2007), depicting the diffusion of methylene blue in
the BLA and DH for rats included in the statistical analysis.
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in contrast, we observed for the ﬁrst time a retention impairment
induced by post-retrieval manipulation in the IA task that could
not be reversed even when animals were given a reminder. Thus,
here we interpret our ﬁndings adopting the term ‘‘reconsolida-
tion’’, as deﬁned operationally by a phenomenon revealed by per-
sistent impairment of memory retention produced by
administration of a protein synthesis inhibitor after retrieval. How-
ever, the relationship between ‘‘consolidation’’ and ‘‘reconsolida-
tion’’ remains a matter of debate and will require further
understanding of their underlying mechanisms. We have proposed
that it may be possible to reconcile apparent discrepant ﬁndings
from different reconsolidation studies by developing a view of con-
solidation and reconsolidation as integrated components of the
processes mediating long-term memory storage (Amaral et al.,
2008; Roesler & McGaugh, 2010). As proposed originally by Dudai
and Eisenberg (2004), and further developed by Alberini (2005,
2011), reconsolidation might be taken as an integral part of a
‘‘lingering consolidation’’ process, and a mechanism triggered by
retrieval to strengthen the consolidation of recently formed
memories.
Our results add to a growing body of evidence, from pharmaco-
logical experiments using rapamycin as well as recent genetic
studies (Stoica et al., 2011), indicating that mTOR is a critical
molecular regulator of synaptic plasticity and memory. The activity
of mTOR is inﬂuenced by N-methyl-D-aspartate (NMDA) glutamate
receptors and brain-derived neurotrophic factor (BDNF), among
other neurotransmitter and neurotrophin pathways. mTOR inte-
grates these signals with downstream signaling pathways such as
the PI3K and phosphoinositide dependent kinase-1 (PDK1), to ulti-
mately lead to alterations in mRNA translation and protein synthe-
sis (reviewed in Hoeffer & Klann, 2010). The role of mTORC1 in
regulating consolidation and reconsolidation of fear memory opens
a window of opportunity for the development of mTORC1 inhibi-
tors as potential therapeutic agents for the treatment of PTSD
and other fear-related psychiatric disorders. Rapamycin is an
mTOR inhibitor already in clinical use as an immunosuppressant,
and has also been investigated in clinical trials of cancer (Lane &Breuleux, 2009). Thus, as previously pointed out by Blundell
et al. (2008), clinical studies of rapamycin combined with reactiva-
tion of traumatic memories in patients with PTSD are warranted.
Rapamycin analogs such as temsirolimus, as well as second-
generation mTOR inhibitors that directly target the mTOR catalytic
site (Guertin & Sabatini, 2009), could also be investigated in
preclinical studies of fear memory as well as in clinical studies in
patients with PTSD.
In conclusion, here we present data consistent with the view
that mTOR is importantly involved in fear memory, and provide
the ﬁrst evidence that mTOR in both the amygdala and hippocam-
pus might play a role in reconsolidation of memory for IA.
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